ClinicalTrials.gg
CompletedNCT02875080Updated Feb 23, 2021Results posted

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

A Phase 1 interventional study of OPC-34712 in Healthy Adult Male, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-23.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The ratios of the geometric means of the ODT formulation to those of the reference formulation (conventional tablet) for the bioavailability variables (Cmax, AUCt, and AUC∞ of brexpiprazole (OPC-34712)).

02

Conditions studied

  • Healthy Adult Male
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of providing written prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all requirements of the trial

Exclusion criteria

Exclusion Criteria:

  • abnormality at the time of screening (eg, significant deviation from reference ranges) or in medical history that, in the opinion of investigator or sponsor may place the subject at risk or interfere with outcome variables, including drug absorption, distribution, metabolism, and excretion
  • History of serious mental disorder
  • History of drug or alcohol abuse within 2 years prior to screening
  • History of any significant drug allergy
  • Use of an drug within 120 days prior to the first dosing of trial drug
  • Use of tobacco products or daily exposure to secondhand smoke within 2 months prior to screening
  • Consumption of grapefruit, grapefruit products, Seville oranges, Seville orange products, starfruit, or starfruit products within 72 hours prior to dosing
  • Use of prescription, over-the-counter, or herbal medication, vitamin supplements, or St. John's Wort within 14 days prior to the first dosing of trial drug, or of antibiotics within 30 days prior to the first dosing of trial drug
  • History of major surgery of the digestive tract (excluding appendectomy)
  • Any subject who, in the opinion of the investigator, should not participate in the trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    OPC-34712 disintegrating tablet with water

    OPC-34712 (4 mg) orally disintegrating tablet is administered with water.

    Drug: OPC-34712

  • Experimental
    OPC-34712 disintegrating tablet without water

    OPC-34712 (4 mg) orally disintegrating tablet is administered without water.

    Drug: OPC-34712

  • Experimental
    OPC-34712 conventional tablet with water

    OPC-34712 (4 mg) conventional tablet is administered with water.

    Drug: OPC-34712

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of OPC-34712

    To evaluate Cmax of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation

    Time frame: Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120,144, 168, 216, 264, and 312 hours postdose

  2. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712

    To evaluate AUC∞ of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation

    Time frame: Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120,144, 168, 216, 264, and 312 hours postdose

07

Results

Posted Feb 23, 2021

Participant flow

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3
Started666
Completed466
Not completed200
Withdrew: Positive urine test for cotinine on day 20 or day 40200

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of OPC-34712

To evaluate Cmax of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation

Time frame:
Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120,144, 168, 216, 264, and 312 hours postdose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of OPC-34712
ng/mLOPC-34712 Disintegrating Tablet With WaterOPC-34712 Disintegrating Tablet Without WaterOPC-34712 Conventional Tablet With Water
Maximum Plasma Concentration (Cmax) of OPC-3471247.4 ± 10.044.9 ± 13.846.1 ± 10.8
PrimaryArea Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712

To evaluate AUC∞ of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation

Time frame:
Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120,144, 168, 216, 264, and 312 hours postdose
Reported as:
Mean · ng·h/mL
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712
ng·h/mLOPC-34712 Disintegrating Tablet With WaterOPC-34712 Disintegrating Tablet Without WaterOPC-34712 Conventional Tablet With Water
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-347122920 ± 16302830 ± 12702770 ± 1460

Adverse events

Collected over From the start of IMP administration throughout follow-up period (up to 22 days after the last dose of IMP). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-34712 Disintegrating Tablet With Water0/16 (0%)0/16 (0%)8/16 (50%)
OPC-34712 Disintegrating Tablet Without Water0/18 (0%)0/18 (0%)7/18 (38.9%)
OPC-34712 Conventional Tablet With Water0/17 (0%)0/17 (0%)9/17 (52.9%)
Most frequent other events
Most frequent other events
EventOPC-34712 Disintegrating Tablet With WaterOPC-34712 Disintegrating Tablet Without WaterOPC-34712 Conventional Tablet With Water
Orthostatic HypotensionVascular disorders4/163/187/17
NauseaGastrointestinal disorders4/165/184/17
VomitingGastrointestinal disorders1/161/180/17
Blood Creatine Phosphokinase IncreasedInvestigations1/160/180/17
DizzinessNervous system disorders1/160/180/17
HeadacheNervous system disorders0/161/180/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence 1Sequence 2Sequence 3Total
Mean32.8 ± 5.529.7 ± 7.428.7 ± 8.030.4 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Sequence 3Total
Female0000
Male66618
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence 1Sequence 2Sequence 3Total
Asian66618
Region of Enrollment
Region of Enrollment(Participants)Sequence 1Sequence 2Sequence 3Total
Japan66618
08

Study locations

1 site
  • Kyusyu Region, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Nov 2016, 2 months.

Results were first posted in Feb 2021, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2016
First posted
Aug 23, 2016
StartActual
Sep 27, 2016
Primary completionActual
Nov 27, 2016
CompletionActual
Nov 27, 2016
Results first posted
Feb 23, 2021
Last update
Feb 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02875080
Responsible party
Sponsor
First posted
Aug 23, 2016
Start date
Sep 27, 2016
Primary completion
Nov 27, 2016
Completion
Nov 27, 2016
Results posted
Feb 23, 2021
Last update
Feb 23, 2021

Study contacts

Hiroaki Ono, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion